-
公开(公告)号：US20220257739A1
公开(公告)日：2022-08-18
申请号：US17728756
申请日：2022-04-25
发明人： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sarah KUTSCHER
IPC分类号： A61K39/00 , A61K38/04 , C07K7/06 , C07K7/00 , C07K7/08 , A61K51/10 , A61K35/17 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , C07K14/435 , C07K14/725 , C07K14/74
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US20220023403A1
公开(公告)日：2022-01-27
申请号：US17502170
申请日：2021-10-15
发明人： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sarah KUTSCHER
IPC分类号： A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K16/18 , C07K7/00 , A61K38/04 , G01N33/68 , C07K14/435 , C07K14/725 , C07K14/74 , A61K35/17 , C07K7/06
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.
-
3.发明申请公开(公告)号：US20190374626A1
公开(公告)日：2019-12-12
申请号：US16552873
申请日：2019-08-27
发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC分类号： A61K39/00 , C12N5/0783 , G01N33/574 , G01N33/68 , C07K16/30 , C07K14/47 , C12N15/115 , C12Q1/6886 , C07K14/725
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
4.发明申请公开(公告)号：US20180207253A1
公开(公告)日：2018-07-26
申请号：US15918788
申请日：2018-03-12
发明人： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sara KUTSCHER
IPC分类号： A61K39/00 , G01N33/68 , C07K14/725 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , A61K35/17 , C12N15/115 , C12N5/0783 , C07K16/18 , C07K14/74 , A61K35/12
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
5.发明申请公开(公告)号：US20170305982A1
公开(公告)日：2017-10-26
申请号：US15638072
申请日：2017-06-29
发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC分类号： C07K14/47 , A61K39/00 , C07K14/725 , C12N5/0783 , C12N15/115 , G01N33/574 , C12Q1/68 , C07K16/30 , A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C07K2319/00 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N33/5748 , G01N33/6848 , G01N2570/00 , G01N2800/52
摘要： A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
-
公开(公告)号：US20220143164A1
公开(公告)日：2022-05-12
申请号：US17587536
申请日：2022-01-28
发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC分类号： A61K39/00 , C12N15/115 , G01N33/574 , C07K14/725 , G01N33/68 , C07K14/47 , C07K16/30 , C12Q1/6886 , C12N5/0783
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20220054613A1
公开(公告)日：2022-02-24
申请号：US17508295
申请日：2021-10-22
发明人： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sarah KUTSCHER
IPC分类号： A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K16/18 , C07K7/00 , A61K38/04 , G01N33/68 , C07K14/435 , C07K14/725 , C07K14/74 , A61K35/17 , C07K7/06
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.
-
公开(公告)号：US20210283230A1
公开(公告)日：2021-09-16
申请号：US17320938
申请日：2021-05-14
发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20210275654A1
公开(公告)日：2021-09-09
申请号：US17320929
申请日：2021-05-14
发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor associated T-cell peptide epitopes, alone or in combination with other tumor associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
10.发明申请公开(公告)号：US20200376103A1
公开(公告)日：2020-12-03
申请号：US16915308
申请日：2020-06-29
发明人： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sara KUTSCHER
IPC分类号： A61K39/00 , A61K38/04 , C07K7/06 , C07K7/00 , C07K7/08 , A61K35/17 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , C07K14/435 , C07K14/725 , C07K14/74
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.025 秒)
